Alefacept (Amevive), produced by Biogen, represents a new drug class for patients with chronic plaque psoriasis. The drug was approved by the U.S. Food and Drug Administration (FDA) on Jan. 31, 2003, and became available on Feb. 3, 2003.
Article Limit Reached
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content